title: Mass Drug Administration for Malaria: A Means to What end?
authors.affiliation: Malaria Elimination Initiative, Global Health Group, University of California-San Francisco.
authors.forename: Ingrid
authors.initials: I
authors.lastname: Chen
authors.affiliation: Malaria Elimination Initiative, Global Health Group, University of California-San Francisco.
authors.forename: Roly
authors.initials: R
authors.lastname: Gosling
authors.affiliation: Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, United Kingdom.
authors.forename: Chris
authors.initials: C
authors.lastname: Drakeley
authors.affiliation: Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, United Kingdom.|Department of Medical Microbiology, Radboud University Nijmegen Medical Center, The Netherlands.
authors.forename: Teun
authors.initials: T
authors.lastname: Bousema
mesh_terms: D000962:Antimalarials; D037621:Artemisinins; D004359:Drug Therapy, Combination; D006801:Humans; D016778:Malaria, Falciparum; D000074381:Mass Drug Administration; D011804:Quinolines
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D011804:Quinolines
keywords: Zambia; dihydroartemisinin-piperaquine; elimination; falciparum